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The heart provides the body with oxygen and nutrients and assists in the removal
of metabolic waste through the blood vessels of the circulatory system. It is the
first organ to form during embryonic morphogenesis. FGFs with diverse functions in
development, health, and disease are signaling proteins, mostly as paracrine growth
factors or endocrine hormones. The human/mouse FGF family comprises 22 members.
Findings obtained frommouse models and human diseases with FGF signaling disorders
have indicated that several FGFs are involved in heart development, health, and disease.
Paracrine FGFs including FGF8, FGF9, FGF10, and FGF16 act as paracrine signals
in embryonic heart development. In addition, paracrine FGFs including FGF2, FGF9,
FGF10, and FGF16 play roles as paracrine signals in postnatal heart pathophysiology.
Although FGF15/19, FGF21, and FGF23 are typical endocrine FGFs, they mainly
function as paracrine signals in heart development or pathophysiology. In heart diseases,
serum FGF15/19 levels or FGF21 and FGF23 levels decrease or increase, respectively,
indicating their possible roles in heart pathophysiology. FGF2 and FGF10 also stimulate
the cardiac differentiation of cultured stem cells and cardiac reprogramming of cultured
fibroblasts. These findings provide new insights into the roles of FGF signaling in the heart
and potential therapeutic strategies for cardiac disorders.
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INTRODUCTION
The heart is a muscular organ that pumps blood. It provides the body with oxygen and nutrients
and assists in the removal of metabolic waste through the blood vessels of the circulatory system.
The heart is the first organ to form during embryonic development. Embryonic heart development
requires proper communication between cardiac progenitor cells (Miquero and Kelly, 2013;
Meganathan et al., 2015). Heart failure, which is a systemic disorder caused by the inability of
the heart to pump blood, represents a major cause of morbidity and mortality and remains a
critical health issue (Wilsbacher andMcNally, 2016). A number of secreted proteins including bone
morphogenetic proteins, insulin-like growth factors, Wnts, vascular endothelial growth factor, and
erythropoietin function as paracrine or endocrine signals in heart development, health, and disease
(Meganathan et al., 2015; Wilsbacher and McNally, 2016).
Fibroblast growth factors (FGFs) are also secreted signaling proteins. In humans and mice,
the FGF family comprises 22 members. Most FGFs play roles as paracrine or endocrine signals
in development, health, and disease in major organs including the liver, kidney, brain, and bone
(Ornitz and Itoh, 2015; Ornitz and Marie, 2015; Brewer et al., 2016; Itoh et al., 2016; Turner et al.,
2016). FGFs also act as paracrine or endocrine signals in heart development, health, and disease.
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These findings provide new insights into the roles of FGFs in
the heart and potential therapeutic strategies for heart disorders.
A succinct review of the roles of FGFs in the heart is provided
herein.
THE FGF FAMILY
The prototypic FGFs, FGF1, and FGF2, are secreted signaling
proteins of ∼150 amino acids. FGF1 and FGF2, which were
originally isolated from the brain as growth factors for fibroblasts,
are expressed in various embryonic and adult tissues and exhibit
diverse activities in cell proliferation, angiogenesis, neuronal cell
growth, and survival, and wound healing. In humans and mice,
22 FGFs of∼150–300 amino acids with a conserved core of∼120
amino acids (∼30–60% amino acid identity) have a wide variety
of functions in development, health, and disease. However, the
human and mouse FGF families do not include FGF15 or FGF19,
respectively, because they are orthologs. Since they have been
named FGF15 in mice and FGF19 in humans, they are typically
referred to as FGF15/19. A phylogenetic analysis has classified
FGFs into seven subfamilies based on their possible evolutionary
relationships. They have also been classified into paracrine,
endocrine, and intracrine FGFs based on their mechanisms of
action (Figure 2; Ornitz and Itoh, 2015; Brewer et al., 2016).
Paracrine FGFs including FGF1-FGF10, FGF16-FGF18,
FGF20, and FGF22 are secreted proteins with heparan sulfate-
binding sites at their carboxyl termini. Paracrine FGFs exert
biological activities by binding to cell surface FGF receptors
(FGFRs) with heparan sulfate as a co-factor (Figure 1A).
Paracrine FGFs mainly function in multiple developmental
and physiological processes by acting on nearby target cells as
local signals via diffusion (Figure 1B). Heparan sulfate with
long linear carbohydrate chains of repeating sulfated glucuronic
acid linked to N-acetylglucosamine disaccharides is covalently
linked to specific cell surface transmembrane-type proteins. It
modulates paracrine FGF diffusion, the modulation of which
directs paracrine FGFs as local signals (Ornitz and Itoh, 2015;
Brewer et al., 2016).
Seven major FGFR proteins (FGFRs 1b, 1c, 2b, 2c, 3b,
3c, and 4) are generated from the FGFR1, FGFR2, FGFR3,
and FGFR4 genes by alternative splicing. FGFRs have different
FGF-binding specificities. Heparan sulfate, which independently
interacts with FGFs and FGFRs, is necessary for stable
interactions between FGFs and FGFRs. The FGF-FGFR-heparan
sulfate complex leads to FGFR dimerization and directs
the activation of FGFR intracellular tyrosine kinase domains
(Figure 1A), followed by key intracellular signaling pathways
including the rat sarcoma protein (RAS)-mitogen-activated
protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)-AKT
serine/threonine kinase (AKT), phospholipase Cγ (PLCγ), and
signal transducer and activator of transcription (STAT) pathways
(Carter et al., 2015; Ornitz and Itoh, 2015; Brewer et al., 2016).
Endocrine FGFs comprising FGF15/19, FGF21, and FGF23
are also secreted proteins (Figure 2). However, endocrine
FGFs do not usually function as local signals due to their
reduced heparan sulfate-binding affinity. Endocrine FGFs
with Klotho-binding sites at their carboxyl termini require
αKlotho or βKlotho as a co-factor for FGFR. Endocrine FGFs
mainly function as endocrine signals in multiple metabolic
processes (Figure 1A). αKlotho and βKlotho, which are single-
pass transmembrane proteins of ∼1000 amino acids with a
short cytoplasmic domain, share structural similarities and
characteristics with each other. They are specifically expressed
in the target tissues of endocrine FGFs, which function in
an endocrine manner with target-tissue specificity through the
bloodstream (Figure 1B; Ornitz and Itoh, 2015). Endocrine FGFs
cannot efficiently bind to FGFR, αKlotho, or βKlotho alone;
they efficiently bind to the FGFR-Klotho complex. FGF15/19
mostly binds FGFR4 with βKlotho and FGF21 mainly binds
FGFR1c with βKlotho. FGF23 mostly binds FGFR1c with
αKlotho. This binding, in turn, induces the activation of the
intracellular signaling pathways of FGFR. FGF15/19 and FGF23
exhibit metabolic and proliferative activities. However, FGF21
is a unique FGF with metabolic, but not proliferative activity
(Itoh et al., 2015; Ornitz and Itoh, 2015). In contrast, intracrine
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FIGURE 1 | Mechanisms of action of paracrine and endocrine FGFs. (A)
Paracrine FGFs specifically bind to the FGFR-heparan sulfate complex and
activate FGFR tyrosine kinase. Endocrine FGFs specifically bind to the
FGFR-Klotho complex and activate tyrosine kinase. This, in turn, induces the
activation of intracellular pathways (Ornitz and Itoh, 2015; Brewer et al., 2016).
(B) Paracrine FGFs are secreted local signals that act on nearby target cells by
diffusion with functions in multiple developmental and pathophysiological
processes. Endocrine FGFs are secreted endocrine signals that act on distant
target cells through the bloodstream with multiple functions in metabolic and
pathophysiological processes. FGFR-HS and FGFR-Klotho indicate the
FGFR-heparan sulfate complex and FGFR-Klotho complex, respectively
(Ornitz and Itoh, 2015; Brewer et al., 2016).
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FIGURE 2 | Evolutionary relationships within the human FGF family.
Phylogenetic analyses suggest that 22 members of the FGF family are
classified into several subfamilies. Branch lengths are proportional to the
evolutionary distance between each FGF. FGFs are also classified into
paracrine, endocrine, and intracrine FGFs based on their mechanisms of
action (Ornitz and Itoh, 2015; Brewer et al., 2016). FGF2, FGF3, FGF8, FGF9,
FGF10, FGF15/19, FGF16, FGF21, and FGF23 play roles in heart
development, health, and disease. This figure is adapted from Itoh et al. (2016).
FGFs comprising FGF11-FGF14 are not secreted signals that play
roles in the regulation of electrical excitability in neurons in an
intracrine manner (Ornitz and Itoh, 2015). Several paracrine and
endocrine FGFs are involved in heart development, health, and
disease, as indicated by findings obtained from mouse models
and human diseases with FGF signaling disorders as described
below.
DEVELOPMENTAL ROLES OF FGFs
INDICATED BY FGF KNOCKOUT MICE
Proper communication between cardiac progenitor cells is
required during embryonic heart development. Remodeling of
the outflow tract, which is derived from two cardiac progenitor
cells, the second heart field and neural crest cells, is essential
for the arterial pole. The second heart field is located in the
pharyngeal mesoderm, which contributes to the growth of the
heart tube during embryonic looping morphogenesis. Neural
crest cells, which migrate from the neuroectoderm of the dorsal
neural tube, contribute to cushion formation, and dictate the
correct septation and alignment of the heart (Miquero and
Kelly, 2013; Meganathan et al., 2015). Among FGFs, FGF3,
FGF8, FGF9, FGF10, FGF15/19, and FGF16 function as paracrine
signals in embryonic heart development (Table 1).
Paracrine Signal
FGF8
FGF8 as a paracrine signal mainly activates FGFR1c with
heparan sulfate as a co-factor in a paracrine manner (Ornitz and
Itoh, 2015). FGF8 is expressed in the early embryonic stages.
TABLE 1 | Developmental roles of FGFs in the embryonic mouse heart.
Function Heart phenotype
PARACRINE SIGNAL
FGF8 Loss-of-function Defect in cardiac looping, the cardiac
outflow tract, and anterior heart field
development
Loss-of-function Decrease in migratory cardiac neural crest
survival
FGF9 Loss-of-function Decrease in cardiomyocyte proliferation
FGF10 Loss-of-function Decrease in cardiomyocyte proliferation
Loss-of-function Decrease in cardiac fibroblast migration
FGF10/FGF3 Loss-of-function Defect in cardiovascular progenitor cell
development
FGF10/FGF8 Loss-of-function Defect in outflow tract and right ventricle
development
FGF15/19 Loss-of-function Defect in cardiac outflow tract
development
FGF16 Loss-of-function Decrease in cardiomyocyte proliferation
Loss-of-function Defect in chamber, atrial, and ventricular
walls and trabeculation
FGF8 knockout mice, which lack all embryonic mesoderm and
endoderm-derived structures, are lethal at the gastrulation stage
(Sun et al., 1999). Findings obtained from FGF8 knockout mice
have also indicated that FGF8 is required for cardiac looping
and migratory cardiac neural crest cell survival. Neural crest cell
deficiencies result in cardiac outflow tract septation defects (Abu-
Issa et al., 2002). FGF8 is also required for anterior heart field
development (Ilagan et al., 2006).
Heparan sulfate is a major constituent of the heart
extracellular matrix. Exostosin glycosyltransferase 1 (Ext1) is
an enzyme that is responsible for the synthesis of heparan
sulfate. The outflow tract defect in mesoderm—specific Ext1
knockout mice has been attributed to the reduced contribution
of the second heart field and neural crest cells. Exogenous FGF8
ameliorates defects in the outflow tract and pharyngeal explants,
indicating that heparan sulfate modulates FGF8 signaling during
early heart development (Zhang R. et al., 2015).
FGF9
FGF9 also mainly activates FGFR1c with heparan sulfate as a
co-factor in a paracrine manner (Ornitz and Itoh, 2015). FGF9
knockout mice are lethal shortly after birth due to impaired
lung development (Colvin et al., 2001). The embryonic hearts of
FGF9 knockout mice are slightly small. FGF9 is expressed in the
mouse embryonic heart. The proliferation of cardiomyocytes is
significantly decreased in the FGF9 knockout heart at embryonic
stages, indicating that FGF9 is a growth factor for embryonic
cardiomyocytes (Lavine et al., 2005).
FGF10
FGF10 preferentially activates FGFR2b with heparan sulfate as
a co-factor in a paracrine manner (Ornitz and Itoh, 2015; Itoh,
2016). FGF10 knockout mice are lethal shortly after birth due to
the lack of multiple organs including limbs and lungs (Sekine
et al., 1999). The embryonic hearts of FGF10 knockout mice
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also showed that altered ventricular morphology is associated
with the impaired proliferation of right, but not left ventricular
cardiomyocytes. FGF10 and FGFR2b are both expressed in
cardiomyocytes, but not cardiac fibroblasts, indicating that
FGF10 regulates regional-specific cardiomyocyte proliferation in
the embryonic heart in an autocrine/paracrine manner (Rochais
et al., 2014). FGF10 is also essential for the movement of cardiac
fibroblasts into the compact myocardium. The inactivation of
the FGF10 signaling pathway results in fewer epicardial-derived
cells within the compact myocardium, decreased myocardial
proliferation, and as a result, a smaller thin-walled heart (Vega-
Hernández et al., 2011).
FGF10 and FGF3 are also both expressed in or near
cardiovascular progenitor cells. The phenotypes of their
knockout mice indicate that FGF10 and FGF3 are required
for the normal developmental coordination of cardiovascular
progenitor cells, but not for their specification (Urness et al.,
2011). In addition, FGF10 and FGF8 are expressed in the anterior
part of the second heart field. The phenotypes of their knockout
mice indicate the functional overlap of FGF10 and FGF8
signaling from second heart field mesoderm during development
of the outflow tract and right ventricle (Watanabe et al., 2010).
FGF15/19
FGF15/19 is expressed in developing pharyngeal arches.
FGF15/19 knockout mice are gradually lethal from embryonic
day 13.5 to postnatal day 7. FGF15/19 knockout mice have heart
defects with malalignment of the aorta and pulmonary trunk.
These defects correlate with early morphological defects in the
outflow tract, indicating that FGF15/19 is required for proper
morphogenesis of the cardiac outflow tract (Vincentz et al.,
2005). FGF15/19 typically activates FGFR4 with βKlotho as an
endocrine signal (Itoh et al., 2015). However, FGFR4 knockout
mice and βKlotho knockout mice, which are alive even during
postnatal stages, do not show any heart defects (Yu et al., 2000;
Ito et al., 2005). These findings indicate that FGF15/19 plays
roles as a paracrine signal in heart development independently
of the FGFR4/βKlotho pathway.
FGF16
FGF16 mainly activates FGFR1c with heparan sulfate as a
co-factor in a paracrine manner (Ornitz and Itoh, 2015).
In mouse embryos, FGF16 is predominantly expressed in
cardiomyocytes. FGF16 knockout mice with the C57 black 6
(C57BL/6) genetic background appear to be normal and fertile.
However, heart weight and cardiomyocyte cell numbers are
slightly decreased, indicating that FGF16 is a growth factor for
embryonic cardiomyocytes. The embryonic heart phenotype is
similar to that of FGF9 knockout mice, suggesting that FGF9 and
FGF16 synergistically act on embryonic cardiomyocytes (Hotta
et al., 2008). In contrast, FGF16 knockout mice with the Swiss
Black genetic background are lethal at embryonic day 11.5 due to
cardiac defects including chamber dilution, thinning of the atrial,
and ventricular walls, and poor trabeculation (Lu et al., 2008).
These different phenotypes may be due to differences in their
genetic backgrounds (Lu et al., 2010).
PATHOPHYSIOLOGICAL ROLES OF FGFs
INDICATED BY FGF KNOCKOUT OR
TRANSGENIC MICE
Cardiac remodeling including cardiac hypertrophy and fibrosis
subsequently progress to heart failure, which represents a major
cause of morbidity and mortality and remains a critical health
issue. Cardiomyokines, heart-derived secreted proteins with
crucial functions for heart function, may play roles in cardiac
remodeling. Cardiomyokines may be therapeutic targets and/or
agents of cardiac remodeling (Doroudgar and Glembotski, 2011).
Among FGFs, FGF2, FGF9, FGF10, FGF16, and FGF21 have been
shown to play pathophysiological roles as cardiomyokines in a
paracrine manner in the heart. However, FGF21 has also been
shown to function in cardiac protection in an endocrine manner
(Table 2).
Paracrine Signal
FGF2
FGF2 mediates biological responses as an extracellular protein by
binding to and activating FGFRs with heparan sulfate as a co-
factor in a paracrine manner (Ornitz and Itoh, 2015). Although
FGF2 is broadly expressed in mice, FGF2 knockout mice are
viable and appear to be normal. However, myocardial infarct-
induced cardiac hypertrophy and fibrosis are protected against in
FGF2 knockout mice (Virag et al., 2007). Isoproterenol-induced
cardiac hypertrophy is also protected against in FGF2 knockout
mice (House et al., 2010). Blood renin and angiotensin II levels
are increased by two-kidney one-clip (2K1C) in mice, leading to
a chronic elevation in blood pressure and compensatory cardiac
hypertrophy. 2K1C-induced cardiac hypertrophy and fibrosis is
also protected against in FGF2 knockout mice (Pellieux et al.,
2001). In addition, cardiac-specific FGF2 transgenic mice exhibit
exacerbated hypertrophy, and this effect is protected against in
TABLE 2 | Pathophysiological roles of FGFs in the postnatal mouse heart.
Function Heart phenotype
PARACRINE SIGNAL
FGF2 Loss-of-function Protection against induced cardiac hypertrophy
and fibrosis Promotion of cardiac
ischemia-reperfusion injury
Gain-of-function Promotion of cardiac hypertrophy
FGF9 Gain-of-function Improvement in heart function
Gain-of-function Protection against heart injury
FGF10 Gain-of-function Protection against heart injury
Gain-of-function Promotion of cardiomyocyte proliferation
FGF16 Loss-of-function Promotion of induced cardiac hypertrophy and
fibrosis
FGF21 Loss-of-function Promotion of induced cardiac hypertrophy and
inflammation
ENDOCRINE SIGNAL
FGF21 Gain-of-function Protection against cardiac dysfunction and
inflammation
Loss-of-function Promotion of cardiac dysfunction and inflammation
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the presence of a pharmacological extracellular signal-regulated
kinase (ERK) inhibitor (House et al., 2010). These findings
indicate that FGF2 promotes cardiac hypertrophy and fibrosis.
In contrast, FGF2 knockout mice subjected to cardiac
ischemia-reperfusion injury have significantly increased
myocardial infarct size and worsened cardiac function, indicating
that FGF2 protects cardiac ischemia-reperfusion injury (House
et al., 2015). The function of FGF2 is mediated by the inhibition
of excessive autophagy and increased ubiquitinated protein
clearance via the activation of the PI3K-AKT signaling pathway
(Wang Z. G. et al., 2015) and also by the suppression of
endoplasmic stress and mitochondrial dysfunction via the
PI3K-AKT and RAS-MAPK signaling pathways (Wang Z. et al.,
2015). The heart expresses FGFR1c, which may be effectively
activated by FGF2 (Fon Tacer et al., 2010; Ornitz and Itoh,
2015). These findings also indicate that FGF2 acts on cardiac
cells in a paracrine manner and promotes cardiac remodeling
by activating the RAS-MAPK and PI3K pathways through the
activation of FGFR1c.
FGF9
Myocardium-specific transgenic FGF9 in mice stimulates
left ventricular hypertrophy with microvessel expansion and
preserves systolic and diastolic functions. After myocardial
infarction, transgenic FGF9 enhances hypertrophy in the
noninfarcted left ventricular myocardium with increased
microvessel density, reduces interstitial fibrosis, attenuates
fetal gene expression, and improves systolic function and heart
failure mortality. However, in cultured rat cardiomyocytes,
FGF9 stimulates the proliferation and network formation of
endothelial cells, but does not directly induce hypertrophic
effects (Korf-Klingebiel et al., 2011).
Monocytes, key mediators of inflammation, differentiate
into pro-inflammatory M1 macrophages, and anti-inflammatory
M2 macrophages upon the infiltration of damaged tissue. A
FGF9 treatment of an infarcted myocardium in db/db diabetic
mice results in significantly decreased monocyte infiltration,
increased M2 macrophage differentiation and associated anti-
inflammatory cytokines, reduced adverse remodeling, and
improved cardiac function. FGF9 possesses novel therapeutic
potential due to its ability to mediate monocyte to M2
macrophage differentiation and confer cardiac protection in the
post-myocardial infarction diabetic heart (Singla et al., 2015).
FGF10
Neonatal mouse hearts have the capacity to regenerate. However,
this capacity quickly decreases after postnatal day 7. The
overexpression of FGF10 in the myocardium of inducible
transgenic mice enhances the expansion of epicardial cells
after heart injury through increased proliferation. However, this
expansion does not lead to increased epithelial-to-mesenchymal
transition or affect fibroblast formation or fibrosis after heart
injury (Rubin et al., 2013). Cardiomyocyte proliferation gradually
decreases during embryogenesis. In FGF10 transgenic mice, the
cell-cycle re-entry of cardiomyocytes, but not cardiac fibroblasts
is promoted, indicating that FGF10 triggers the cell-cycle re-entry
of cardiomyocytes in adults, and is, thus, a potential target for
cardiac repair (Rochais et al., 2014).
FGF16
Cardiac hypertrophy and fibrosis are induced by angiotensin
II. Transforming growth factor-β1 (TGF-β1) is a downstream
factor of angiotensin II for cardiac hypertrophy and fibrosis.
Angiotensin II-induced cardiac hypertrophy and fibrosis are
significantly promoted by increasing the expression of TGF-β1
in FGF16 knockout mice (Matsumoto et al., 2013). The response
to cardiac remodeling in FGF16 knockout mice is apparently
opposite to that in FGF2 knockout mice as described above
(Pellieux et al., 2001).
In the heart, FGF16 and FGF2 are mainly expressed in
cardiomyocytes and non-cardiomyocytes, respectively. FGF16 is
a cardiomyocyte-derived paracrine signal (Hotta et al., 2008).
FGF2 stored in non-cardiomyocytes is released in response to
hemodynamic stress (Kaye et al., 1996). FGF2 exhibits significant
proliferative activity in cultured cardiomyocytes, where FGF16
does not. However, FGF16 inhibits the activity of FGF2 by
competing with FGF2 for FGFR1c, which is predominantly
expressed in the heart (Lu et al., 2008). Furthermore, FGF2
significantly induces the expression of TGF-β1 in cultured
cardiomyocytes and non-cardiomyocytes, where FGF16 does
not. However, FGF16 inhibits the FGF2-induced expression of
TGF-β1. The biochemical properties of FGF16 are distinct from
those of FGF2. Cardiac FGF16 expression is induced after that
of FGF2 by angiotensin II. FGF16 expression is promoted by
FGF2 in cultured cardiomyocytes. These findings indicate that
FGF16 prevents cardiac hypertrophy and fibrosis by competing
with FGF2 for FGFR1c (Itoh and Ohta, 2013; Matsumoto et al.,
2013; Wang J. et al., 2015).
GATA binding protein (GATA) family members are zinc
finger transcription factors. GATA4 regulates a number of
cardiac-specific genes that are important for embryonic and
neonatal heart development. Ventricular function accompanied
by reduced cardiomyocyte replication in the heart is severely
depressed in inducible cardiomyocyte-specific GATA4 knockout
mice after injury. After injury, the mutant hearts also display
impaired coronary angiogenesis and increased hypertrophy
and fibrosis with a significant reduction in the expression of
FGF16. The cardiac-specific overexpression of FGF16 in the
mutant hearts partially rescues cardiac hypertrophy, promotes
cardiomyocyte replication, and improves heart function after
injury, indicating that GATA4 is required for neonatal heart
regeneration through the regulation of FGF16, which has
potential in promoting myocardial repair (Yu et al., 2016).
FGF21
FGF21 functions in an FGFR-dependent manner. However,
FGF21 binds to FGFRs with heparan sulfate with very low
affinity. FGF21 efficiently activates FGFR1c with βKlotho as a
co-factor. FGF21 acts on long-distance targeted cells through
blood cells in an endocrine manner. FGF21 is mainly expressed
in the liver. The phenotypes of FGF21 knockout and transgenic
mice suggest the diverse metabolic actions of FGF21 in glucose
and lipid metabolism in an endocrine manner (Itoh et al., 2015;
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Kharitonenkov and DiMarchi, 2015). However, FGF21 acts s as a
paracrine signal in the heart as described below.
An increased relative heart weight and enhanced signs
of dilatation are observed in FGF21 knockout mice. Cardiac
hypertrophy is also more enhanced in response to the infusion
of isoproterenol in FGF21 knockout mice. FGF21 reverses
cardiac hypertrophy in FGF21 knockout mice and cultured
cardiomyocytes. Although cardiomyocytes produce FGF21,
cardiac FGF21 secretion is lower than hepatic FGF21 secretion.
However, FGF21 is abundantly secreted by cardiac cells in
response to cardiac stress, and cardiac FGF21 secretion inhibits
isoproterenol-induced cardiac hypertrophic damage. In addition,
FGFR1c and βKlotho are both predominantly expressed in
cardiomyocytes. These findings indicate that FGF21 acts on
cardiomyocytes, possibly in a paracrine manner, and prevents
cardiac hypertrophy by activating MAPK signaling through the
activation of FGFR1c with βKlotho (Planavila et al., 2013, 2015a).
Oxidative stress by reactive oxygen species plays a prominent
role in the pathogenesis of heart failure, and antioxidants
attenuate cardiac remodeling. The expression of antioxidant
genes in response to the lipopolysaccharide (LPS)-induced
stimulation of pro-inflammatory pathways or isoproterenol-
induced cardiac hypertrophy is decreased in the hearts of FGF21
knockout mice. In cultured cardiomyocytes, FGF21 induces
the expression of genes involved in antioxidative pathways.
FGF21 released by cardiomyocytes in response to LPS acts
in an autocrine/paracrine manner to protect cells against
oxidative stress. These findings indicate that FGF21, as an
autocrine/paracrine signal, prevents induction of pro-oxidative
pathways in the heart (Di Lisa and Itoh, 2015; Planavila et al.,
2015a,b).
Cardiac FGF21 expression is increased in a mouse model of
type 1 diabetes. FGF21 knockout mice are more susceptible to
diabetes-induced cardiac apoptosis, and this may be prevented
by the administration of FGF21. FGF21 significantly reduces
palmitate-induced cardiac apoptosis in cultured cardiomyocytes.
Palmitate suppresses, whereas FGF21 promotes the MAPK
pathway. These findings indicate that FGF21 prevents lipid-
or diabetes-induced cardiac apoptosis by activating the MAPK
pathway (Zhang C. et al., 2015). Fenofibrate, which is a
peroxisome proliferator-activated receptor (PPAR) α agonist, is
clinically used to lower lipid levels. Fenofibrate prevents diabetes-
induced cardiac dysfunction, inflammation, and remodeling
in streptozotocin-induced type 1 diabetic mice. Fenofibrate
also increases the cardiac expression of FGF21 and sirtuin 1.
Diabetes-induced pathogenic effects in the heart are enhanced
in FGF21 knockout mice. Fenofibrate lowers the systemic
lipid profile, but does not prevent heart deterioration in
FGF21 knockout diabetic mice. Exposure to high glucose
levels significantly increases inflammatory responses, oxidative
stress, and pro-fibrotic responses and also significantly inhibits
autophagy in a cultured cardiomyocyte cell line. These effects
are prevented by fenofibrate. This prevention is abolished by the
inhibition of sirtuin 1. Thus, FGF21 prevents type 1 diabetes-
induced pathological and functional cardiac abnormalities by
up-regulating sirtuin 1-mediated autophagy (Zhang et al., 2016).
These findings also indicate that FGF21 plays roles in cardiac
protection in a paracrine manner. However, conflicting findings
have shown that FGF21 is involved in cardiac protection in an
endocrine manner as described below.
Endocrine Signal
FGF21
Myocardial ischemia with cardiomyocyte injury activates innate
protective processes, which enhance myocardial tolerance to
ischemia. In mice, FGF21 is released from hepatocytes and
adipocytes into the circulation, and then contributes to
myocardial protection through the mediation of the FGFR1/β-
Klotho-PI3K-Akt1-BLC2-associated agonist of cell death (BAD)
signaling network in an endocrine manner (Liu et al., 2013).
Skeletal muscle is also an important site for the production
of FGF21. The overexpression of FGF21 by adenoviral vectors
in the skeletal muscle of mice (Ad-FGF21 mice) improves left
ventricular systolic dysfunction and dilatation in a mouse model
of myocardial infarction. Serum levels of adiponectin, which
is a cardioprotective adipokine, are increased in Ad-FGF21
mice. The beneficial effects of Ad-FGF21 on cardiac dysfunction
and inflammatory responses after myocardial infarction are
diminished in adiponectin-knockout mice, indicating that
muscle-derived FGF21 ameliorates adverse cardiac remodeling
after myocardial infarction, at least in part, through an
adiponectin-dependent mechanism (Joki et al., 2015).
Serum FGF21 levels are significantly decreased in
streptozotocin-diabetic mice, however, no significant difference
has been reported in blood glucose and triglyceride levels
between FGF21 knockout and control diabetic mice. FGF21
knockout diabetic mice show earlier and more severe cardiac
dysfunction, remodeling, and oxidative stress, as well as greater
increases in cardiac lipid accumulation, which may contribute
to increased cardiac oxidative stress and remodeling and the
eventual development of diabetic cardiomyopathy (Yan et al.,
2015).
Dietary methionine restriction (MR) mice exhibit
hyperhomocysteinemia, which is a symptom associated with an
increased risk of cardiovascular disease. However, an MR diet
does not alter cardiac function in mice in spite of the presence of
hyperhomocysteinemia. An MR diet induces the secretion of the
cardioprotective hormones, adiponectin and FGF21, indicating
that the adaptive responses of increased serum adiponectin and
FGF21 levels protect against hyperhomocysteinemia (Ables et al.,
2015).
PATHOPHYSIOLOGICAL ROLES OF FGFs
INDICATED BY HUMAN DISEASES
FGF signaling disorders result in various human diseases
including inherited diseases, metabolic diseases, and cancers
(Carter et al., 2015; Ornitz and Itoh, 2015; Brewer et al., 2016;
Degirolamo et al., 2016). Signaling disorders of FGF2, FGF21,
and FGF23 as paracrine signals also result in heart diseases. In
addition, heart diseases affect serum levels of FGF15/19, FGF21,
and FGF23, indicating that these FGFs are serum biomarkers for
heart diseases (Table 3).
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 October 2016 | Volume 4 | Article 110
Itoh et al. FGF Signals in the Heart
TABLE 3 | Pathophysiological roles of FGFs in the human heart.
Function Effect Disease
PARACRINE SIGNAL
FGF2 Gain-of-function Promotion Inflammatory pericardial disease
Gain-of-function Promotion Type 4 cardiorenal syndrome
Gain-of-function Protection TGFβ1-induced cardiac
remodeling
FGF16 Loss-of-function Promotion Myocardial infarction and atrial
fibrillation
FGF21 Gain-of-function Atrial fibrillation with rheumatic
heart disease
FGF23 Gain-of-function Promotion Left ventricular hypertrophy
Serum levels Disease
SERUM BIOMARKER
FGF15/19 Decrease Coronary artery disease
FGF21 Increase Coronary artery disease
FGF23 Increase Acute decompensated heart failure
Increase Kawasaki syndrome
Increase Left ventricular hypertrophy
Increase Oncostatin-dependent heart
disease
Paracrine Signal
FGF2
Pericardial effusion is the abnormal accumulation of fluid in the
pericardial cavity. Fluid accumulation leads to an increase in
intrapericardial pressure, which has negative impacts on heart
function. FGF2 levels in pericardial effusion are elevated in
patients with inflammatory pericardial effusion. FGF2 has been
suggested to participate in the pathogenesis of inflammatory
pericardial disease (Karatolios et al., 2012).
Type 4 cardiorenal syndrome (CRS) refers to the cardiac
injury induced by chronic kidney disease (CKD). Patients
with type 4 CRS show elevated oxidative stress, which
correlates with cardiac hypertrophy and a decreased ejection
fraction. 5/6 subtotal nephrectomy rats mimic type 4 CRS.
Cardiac FGF2, ERK1/2 phosphorylation, and nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity
are significantly increased in 5/6 subtotal nephrectomy rats,
suggesting that cardiac injury in type 4 CRS is mediated by an
NADPH oxidase-dependent oxidative stress-activated ERK1/2
pathway and subsequent up-regulation of FGF2 (Liu et al., 2015).
Sustained elevations in pro-fibrotic TGFβ1 induces cardiac
myofibroblast-mediated fibrosis and progressive structural
tissue remodeling. Transforming growth factor (TGF) β1
significantly induces myofibroblast activation and extracellular
matrix dysregulation. FGF2 attenuates TGFβ1-induced cardiac
myofibroblast-mediated extracellular matrix remodeling in
humans, suggesting that FGF2 prevents progressive maladaptive
chamber remodeling and tissue fibrosis in patients with diverse
structural heart diseases (Svystonyuk et al., 2015).
FGF16
FGF16 loss-of-function mutations are linked to X-linked
recessive hand malformations with fusion between the fourth
and fifth metacarpals and hypoplasia of the fifth digit. Cardiac
disorders including myocardial infarction and atrial fibrillation
follow the FGF16mutated trait, indicating a relationship between
the FGF16 mutation and cardiac disease (Laurell et al., 2014).
FGF21
Although FGF21 is a typical endocrine signal, FGF21 in the heart
may function as a paracrine signal as described above. Atrial
fibrillation, which is the most common persistent arrhythmia,
is a common manifestation of cardiovascular diseases including
rheumatic heart disease. FGF21 expression levels in atrial tissue
and serum FGF21 levels are significantly increased in atrial
fibrillation patients with rheumatic heart disease, indicating that
FGF21 is involved in the development and maintenance of atrial
fibrosis in atrial fibrillation with rheumatic heart disease in a
paracrine manner (Wang R. et al., 2015).
FGF23
FGF23 typically regulates phosphate and vitamin D metabolism
as a bone-derived hormone by mediating its biological responses
in an FGFR-dependentmanner. However, FGF23 binds to FGFRs
with heparan sulfate with very low affinity. FGF23 efficiently
binds to and activates FGFR1c with αKlotho as a co-factor
(Erben, 2016). Although FGF23 is a typical endocrine signal,
FGF23 in the heart may act as a paracrine signal as described
below.
The levels of cardiac FGF23, which is expressed in
cardiomyocytes, are excessively high in CKD patients. The
enhanced myocardial expression of FGF23 strongly correlates
with the presence of left ventricular hypertrophy (LVH). Cardiac
FGF23 levels are associated with the up-regulation of FGFR4
and activation of the calcineurin-NFAT signaling pathway, an
established mediator of cardiac remodeling and LVH, indicating
a strong relationship between LVH and elevated expression
levels of FGF23, FGFR4, and calcineurin, as well as the
activation of nuclear factor of activated T cells (NFAT) in the
myocardium of patients with CKD (Leifheit-Nestler et al., 2016).
FGF23 exclusively activates FGFR4 on human cardiomyocytes.
A specific FGFR4-blocking antibody inhibits FGF23-induced
hypertrophy in isolated cardiomyocytes and attenuates LVH in
rats with CKD. FGFR4 knockout mice do not develop LVH in
response to elevated FGF23, whereas FGFR4 knockin mice with
an FGFR4 gain-of-function mutation spontaneously develop
LVH. These findings indicate that FGF23 promotes LVH by
activating FGFR4 in a paracrine manner (Grabner et al., 2015).
Serum Biomarkers
FGF15/19
FGF15/19 is a potential regulator of glucose and lipid
metabolism, which may lead to atherosclerosis. Serum FGF15/19
levels are decreased in patients withmetabolic syndrome, obesity,
and non-alcoholic fatty liver disease (NAFLD) (Itoh et al., 2015;
Zhang F. et al., 2015; Nies et al., 2016). Coronary artery disease
(CAD) is an ischemic heart disease including stable angina,
unstable angina, myocardial infarction, and sudden cardiac
death. Serum FGF15/19 levels are negatively associated with the
presence and severity of CAD, indicating that serum FGF15/19
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levels are independent predictors of the extent of CAD (Hao et al.,
2013).
FGF21
Serum FGF21 levels are significantly increased in CAD patients
and are independently associated with adverse lipid metabolism
(Lin et al., 2010). Serum FGF21 levels are also increased with
NAFLD, metabolic disorders, and types 2 diabetes as well as CAD
(Shen et al., 2013; Kim et al., 2015). However, by strictly matching
body mass indices, serum FGF21 levels correlate in patients
with metabolic disorders, but not CAD, indicating that this
relationship is attributed more to preexisting cardio-metabolic
factors than CAD per se (Lee et al., 2014; Domouzoglou et al.,
2015).
FGF23
Serum FGF23 levels are also markedly elevated in patients with
acute decompensated heart failure (ADHF), which is a sudden
worsening of the signs and symptoms of heart failure, including
difficulty breathing, leg or feet swelling, and fatigue (Andersen
et al., 2016), with heart failure and a reduced ejection fraction
(Koller et al., 2015), incident atrial fibrillation (Mathew et al.,
2014), coronary heart disease, heart failure, and cardiovascular
mortality (Lutsey et al., 2014), non-ischemic cardiac disease
(Imazu et al., 2014), chronic systolic heart failure (Wohlfahrt
et al., 2015), and CAD (Tuñón et al., 2016). However, myocardial
FGF23 gene expression levels and FGF23 immunostaining are
not increased in ADHF patients, suggesting that the myocardium
does not contribute to elevated circulating FGF23 levels in ADHF
and that FGF23 plays roles in heart failure in an endocrine
manner (Andersen et al., 2016).
Kawasaki syndrome is a vascular inflammatory disease that
is associated with an increased risk of developing subsequent
cardiac abnormalities in childhood. Patients often have elevated
serum FGF23 levels with FGF23 polymorphisms, which are
correlated with cardiac abnormalities (Falcini et al., 2013; Masi
et al., 2013).
Serum FGF23 levels, which are elevated with the progression
of CKD, are associated with left ventricular hypertrophy (LVH),
a major contributor to cardiovascular disease (Jimbo and
Shimosawa, 2014; Wyatt and Drüeke, 2016). FGF23 causes
pathological hypertrophy in isolated rat cardiomyocytes via
the FGF receptor-dependent activation of the calcineurin-
NFAT signaling pathway, which is independent of αKlotho.
An intramyocardial or intravenous injection of FGF23 in mice
results in LVH. In an animal model of CKD, a treatment with an
FGF-receptor blocker attenuates LVH. The causal role for FGF23
in the pathogenesis of LVH suggests that chronically elevated
serum FGF23 levels contribute directly to high rates of LVH and
mortality in individuals with CKD (Faul et al., 2011; Faul, 2012).
Oncostatin M (OSM) is a major mediator of cardiac
remodeling in heart failure. However, serum OSM levels are too
low to serve as a suitable biomarker. FGF23 has been identified
as a target of OSM in cultured cardiomyocytes. Serum FGF23
levels are increased in patients with myocarditis and ischemic
and dilated cardiomyopathy. The macrophage/OSM axis is the
major mechanism of cardiac FGF23 expression and release into
the circulation in heart failure, indicating that FGF23 as a
paracrine signal is a promising biomarker of OSM-dependent
heart diseases (Richter et al., 2015).
Therapeutic Potential
Although the therapeutic potential of FGFs in cardiac disorders
has been indicated by animal models described above, it has
not been reported in humans. However, the findings by animal
models provide therapeutic strategies for cardiac disorders in
humans.
ROLES OF FGFs IN STEM CELL BIOLOGY
Embryonic Stem Cells and Induced
Pluripotent Stem Cells
Embryonic stem (ES) and induced pluripotent stem (iPS) cells
have multipotency to differentiate into various cell lineages
(Takahashi and Yamanaka, 2015). Cells and tissues differentiated
from ES and iPS cells have potential as a novel therapy for
advanced heart failure (Liu et al., 2016; Terzic and Behfar, 2016).
FGF2 and FGF10 enhance the cardiomyogenic differentiation of
stem cells, indicating that FGF signaling is useful for stem cell
therapy for heart failure.
FGF2
The combination of FGF2 and BMP2 efficiently enhances
the cardiomyogenic differentiation of ES cells at an optimal
concentration for the first 3 days. The inhibition of FGF2
markedly suppresses cardiomyogenic differentiation, indicating
that FGF signaling plays a crucial role in early cardiomyogenesis
(Kawai et al., 2004). FGF2 and BMP2 also induce iPS cell
differentiation into cardiomyocytes (Yamasaki et al., 2013). The
achievement of efficient cardiac differentiation using FGF2 may
facilitate ES or iPS cell-derived cell therapy for heart diseases.
FGF10
FGF10 also promotes cardiomyocyte differentiation from ES and
iPS cells. In addition, co-administration of FGF10 and ES cells in
the myocardium promotes cardiomyocyte differentiation in the
heart (Chan et al., 2010).
Direct Reprogramming from Fibroblasts
One cell type may be directly converted into another without
reverting to a stem cell state by overexpressing lineage-specific
factors. Direct reprogramming has been proven sufficient
for yielding a diverse range of cell types from fibroblasts,
including cardiomyocytes, endothelial cells, hematopoietic cells,
and stem/progenitor cells (Sadahiro et al., 2015). Direct
reprogramming is also potentially useful as a novel therapy for
advanced heart failure.
FGF2 and FGF10
Fibroblasts may be directly reprogrammed into cardiomyocyte-
like cells by the overexpression of cardiac transcription factors,
however, this process is inefficient under serum-based culture
conditions. The combination of FGF2, FGF10, and vascular
endothelial growth factor promotes cardiac reprogramming
under defined serum-free conditions. The combination of
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these secreted signals activates multiple cardiac transcriptional
regulators and converts partially reprogrammed cells into
functional cardiomyocyte-like cells through the RAS-MAPK and
PI3K/AKT pathways (Yamakawa et al., 2015).
CONCLUSIONS
FGFs are paracrine growth factors, hormone-like endocrine
factors, and intracrine factors with diverse functions in
development, health, and disease. Findings obtained frommouse
models and human diseases with FGF signaling disorders have
indicated that several FGFs are involved in heart development,
health, and disease. FGF8, FGF9, FGF10, and FGF16 function as
paracrine signals in embryonic heart development. In addition,
FGF2, FGF9, FGF10, and FGF16 play roles as paracrine signals
in postnatal heart pathophysiology. Although FGF15/19, FGF21,
and FGF23 are endocrine FGFs, they also mostly act as
paracrine signals in heart development or pathophysiology.
Serum FGF15/19 levels are decreased and FGF21 and FGF23
levels are increased in heart diseases, which also suggests
their roles in heart pathophysiology. In addition, FGF2 and
FGF10 stimulate the cardiac differentiation of cultured stem
cells and cardiac reprogramming of cultured fibroblasts. These
findings provide new insights into the roles of FGF signaling
in the heart and potential therapeutic strategies for cardiac
disorders.
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